EQL's melatonin is a prescription drug used to treat insomnia in children 6 - 17 years with ADHD where other sleep support measures are not sufficient. It can also be taken by adults to treat the effects of jet lag for a short time.
The Norwegian market currently has two registered competitors, one of which with only the jet lag indication, and sales of approximately 56mNOK with an annual growth of approximately 40%. The Danish market has three registered competitors, two of which have only the jet lag indication. Sales in Denmark are about 33mDKK with an annual growth of about 55%.
For further information, please contact:
Christer Fåhraeus
CEO,
Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
https://news.cision.com/eql-pharma/r/eql-pharma-s-melatonin-tablets-approved-in-denmark-and-norway,c3519171
https://mb.cision.com/Main/11664/3519171/1544532.pdf
(c) 2022 Cision. All rights reserved., source